Wide Ranks

EVO

Evotec SE

4.83

Top Statistics
Market Cap 1 B Forward PE -11.50 Revenue Growth -5.80 %
Current Ratio 2.09 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -22.05 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 64.35 Enterprise / Revenue 1.32 Price To Sales Trailing12 Months 2.21
Profitability
Profit Margins -22.05 % Operating Margins -17.68 %
Balance Sheet
Total Cash 303 M Total Cash Per Share 1.71 Total Debt 470 M
Total Debt To Equity 48.53 Current Ratio 2.09 Book Value Per Share 5.46
All Measures
Short Ratio 140.00 % Message Board Id finmb_531375 Fax 49 40 560 81 222
Shares Short Prior Month 246487 Return On Equity -0.1625 City Hamburg
Uuid d38f92ff-a363-3ec4-a23c-74ec13c26d06 Previous Close 4.76 First Trade Date Epoch Utc 1 B
Book Value 5.46 Beta 0.9840 Total Debt 470 M
Volume 143673 Price To Book 0.8845 Last Split Date 1 B
Fifty Two Week Low 2.85 Total Cash Per Share 1.71 Total Revenue 777 M
Shares Short Previous Month Date 1 B Target Median Price 7.42 Max Age 86400
Recommendation Mean 2.20 Sand P52 Week Change 0.3133 Operating Margins -17.68 %
Target Mean Price 6.62 Net Income To Common -171370000 Short Percent Of Float 0.0014
Implied Shares Outstanding 419 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 481240 Average Volume10days 481240 Total Cash 303 M
Next Fiscal Year End 1 B Revenue Per Share 2.19 Ebitda Margins 2.05 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 4.76 Target Low Price 3.59 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.90 Open 4.84 Free Cashflow -188424880
Dividend Yield 0.00 % Return On Assets -0.0177 Time Zone Short Name EST
Trailing Eps -0.5100 Day Low 4.78 Address1 Essener Bogen 7
Shares Outstanding 355 M Price Hint 4 Target High Price 9.32
Website https://www.evotec.com 52 Week Change -0.5175 Average Volume 198153
Forward Eps -0.1900 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 159.20 % Last Split Factor 4:1 Regular Market Day High 4.89
Is_sp_500 False Profit Margins -22.05 % Debt To Equity 48.53
Fifty Two Week High 12.00 Day High 4.89 Shares Short 449696
Regular Market Open 4.84 Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 %
Enterprise To Revenue 1.32 Revenue Growth -5.80 % Shares Percent Shares Out 0.0013
Operating Cashflow -36055000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 22419
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name Evotec SE
Regular Market Day Low 4.78 Held Percent Institutions 0.0234 Current Price 4.83
Enterprise To Ebitda 64.35 Financial Currency EUR Current Ratio 2.09
Gross Margins 13.70 % Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 5
Country Germany Float Shares 129 M Two Hundred Day Average 5.01
Enterprise Value 1 B Price To Sales Trailing12 Months 2.21 Forward PE -11.50
Regular Market Volume 143673 Ebitda 15 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.

The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.

Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.